Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kymera Therapeutics (KYMR) Leases (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Leases for 8 consecutive years, with $41.7 million as the latest value for Q1 2026.

  • For Q1 2026, Leases fell 10.69% year-over-year to $41.7 million; the TTM value through Mar 2026 reached $41.7 million, down 10.69%, while the annual FY2025 figure was $42.4 million, 10.67% down from the prior year.
  • Leases hit $41.7 million in Q1 2026 for Kymera Therapeutics, down from $42.4 million in the prior quarter.
  • Across five years, Leases topped out at $56.6 million in Q1 2023 and bottomed at $8.9 million in Q4 2022.
  • Average Leases over 5 years is $39.4 million, with a median of $46.7 million recorded in 2025.
  • Year-over-year, Leases skyrocketed 508.19% in 2023 and then dropped 12.85% in 2024.
  • Kymera Therapeutics' Leases stood at $8.9 million in 2022, then soared by 494.29% to $52.9 million in 2023, then decreased by 10.46% to $47.4 million in 2024, then fell by 10.67% to $42.4 million in 2025, then fell by 1.45% to $41.7 million in 2026.
  • According to Business Quant data, Leases over the past three periods came in at $41.7 million, $42.4 million, and $42.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.